Veru(VERU) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: veruinvestor@verupharma.com Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress —Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 — —Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second quarter of calendar 2025 — —With positive Phase 2b QUALITY study, Ve ...